Natixis Increases Position in Moderna, Inc. (NASDAQ:MRNA)

Natixis increased its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 78.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 113,966 shares of the company's stock after buying an additional 49,953 shares during the period. Natixis' holdings in Moderna were worth $4,739,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Allworth Financial LP grew its stake in shares of Moderna by 17.3% in the fourth quarter. Allworth Financial LP now owns 1,901 shares of the company's stock valued at $73,000 after acquiring an additional 281 shares in the last quarter. Howard Capital Management Inc. increased its holdings in shares of Moderna by 3.1% during the fourth quarter. Howard Capital Management Inc. now owns 9,994 shares of the company's stock worth $416,000 after purchasing an additional 297 shares during the period. Commonwealth Equity Services LLC increased its holdings in shares of Moderna by 0.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company's stock worth $3,099,000 after purchasing an additional 345 shares during the period. Larson Financial Group LLC boosted its stake in shares of Moderna by 39.1% in the fourth quarter. Larson Financial Group LLC now owns 1,266 shares of the company's stock valued at $53,000 after buying an additional 356 shares during the period. Finally, New Insight Wealth Advisors grew its position in Moderna by 4.4% during the fourth quarter. New Insight Wealth Advisors now owns 8,545 shares of the company's stock worth $355,000 after buying an additional 358 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.

Moderna Trading Down 0.6 %

Shares of MRNA traded down $0.17 during trading hours on Friday, reaching $27.22. 7,714,270 shares of the stock traded hands, compared to its average volume of 7,343,319. The company has a market cap of $10.52 billion, a P/E ratio of -2.93 and a beta of 2.23. The company's 50-day moving average price is $30.19 and its two-hundred day moving average price is $38.64. Moderna, Inc. has a 52-week low of $23.15 and a 52-week high of $170.47.

Analysts Set New Price Targets

Several equities analysts have commented on MRNA shares. UBS Group decreased their target price on shares of Moderna from $96.00 to $78.00 and set a "buy" rating on the stock in a report on Wednesday, February 19th. Evercore ISI set a $50.00 target price on Moderna in a report on Friday, February 14th. JPMorgan Chase & Co. decreased their price target on Moderna from $40.00 to $33.00 and set an "underweight" rating on the stock in a research note on Friday, March 21st. Bank of America dropped their price objective on Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a research report on Tuesday, February 11th. Finally, Barclays cut Moderna from an "overweight" rating to an "equal weight" rating and decreased their target price for the company from $111.00 to $45.00 in a research report on Tuesday, February 18th. Four research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $58.70.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.